Sign In
Buy TXG
$31.75
-0.470 (-1.46%)
At Close: Jun 16, 2026
10x Genomics Reports First Quarter 2024 Financial Results
04:05pm, Tuesday, 30'th Apr 2024
PLEASANTON, Calif. , April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 3
3 Medical Products Stocks Set to Beat This Earnings Season
12:31pm, Friday, 26'th Apr 2024
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
Down -23.92% in 4 Weeks, Here's Why 10x Genomics (TXG) Looks Ripe for a Turnaround
10:36am, Wednesday, 24'th Apr 2024
10x Genomics (TXG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimat
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Tuesday, 23'rd Apr 2024
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Upgraded to Buy: Here's What You Should Know
01:01pm, Monday, 22'nd Apr 2024
10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
04:05pm, Wednesday, 10'th Apr 2024
PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first q
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
09:00am, Tuesday, 26'th Mar 2024
Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genom
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
04:05pm, Thursday, 21'st Mar 2024
Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
04:05pm, Wednesday, 13'th Mar 2024
The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 1
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.
Cathie Wood Just Bought These 3 Biotech Stocks. Should You Buy, Too?
02:00pm, Friday, 01'st Mar 2024
The U.S. spends approximately $450 billion every year treating rare diseases. Investing guru Cathie Wood says managing patients afflicted with these illnesses could cost $20 trillion over their lifeti
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
11:55am, Tuesday, 27'th Feb 2024
Ark Invest bought shares of Roku, 10x Genomics, and Intellia Therapeutics on Monday. Roku has shed more than one-third of its value over the past two weeks after a series of unfortunate events.
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
04:05pm, Tuesday, 20'th Feb 2024
PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
11:55pm, Thursday, 15'th Feb 2024
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About 10x Genomics (TXG) Q4 Earnings
07:01pm, Thursday, 15'th Feb 2024
Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall
